{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:20:40Z","timestamp":1793409640459,"version":"4.5.0"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u00f3w Slaskich we Wroclawiu","doi-asserted-by":"publisher","award":["SUBZ.C200.24.086"],"award-info":[{"award-number":["SUBZ.C200.24.086"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Paroxysmal nocturnal hemoglobinuria (PNH) is a rare complement-driven acquired hemolytic anemia with specific presentations of hemoglobinuria, abdominal pain, fatigue, and thrombosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review the current therapeutic strategies for PNH, including anti-complement therapy and allogeneic hematopoietic cell transplantation (alloHCT), focusing on the tailoring of the approach to the disease subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The outcome of alloHCT varies depending on disease severity, thrombotic history, and response to prior therapies. Non-transplant PNH therapies include anti-C5 monoclonal antibodies that reduce terminal complement activation (eculizumab, ravulizumab, and crovalimab) and proximal complement pathway inhibitors such as pegcetacoplan (C3 inhibitor), iptacopan (complement factor B inhibitor), and danicopan (complement factor D inhibitor). Although complement inhibitors have revolutionized treatment, alloHCT remains the only curative therapy, particularly for patients who are refractory to medical management or have severe cytopenia. This review outlines the conditioning regimens used in alloHCT and summarizes recent studies showing that overall survival rates improve with less toxic conditioning protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AlloHCT can be used to manage PNH, particularly in patients who are resistant to or without access to complement-targeted therapies. Any potential cure offered by alloHCT must be counterbalanced by the significant procedure risks, including graft-versus-host disease and transplant-related mortality, particularly in patients with comorbidities. In the case of severe aplastic anemia with an associated PNH clone, immunoablative protocols based on anti-thymocyte globulin serotherapy with fludarabine and cyclophosphamide are recommended. The use of reduced toxicity protocols with fludarabine has been well-documented in patients with classic PNH. A treosulfan\/fludarabine-based regimen is recommended; however, there is no consensus on optimal drug selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1521484","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T02:18:44Z","timestamp":1736216324000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Current status and perspectives of hematopoietic cell transplantation in patients with paroxysmal nocturnal hemoglobinuria"],"prefix":"10.3389","volume":"15","author":[{"given":"Marek","family":"Ussowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawid","family":"Przystupski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Mensah-Glanowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Piekarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2012.01.004","article-title":"GPI-anchor remodeling: Potential functions of GPI-anchors in intracellular trafficking and membrane dynamics","volume":"1821","author":"Fujita","year":"2012","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Biol Lipids."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013519","article-title":"Constitutional PIGA mutations cause a novel subtype of hemochromatosis in patients with neurologic dysfunction","volume":"139","author":"Muckenthaler","year":"2022","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16545","article-title":"Lessons learned from 40 novel PIGA patients and a review of the literature","volume":"61","author":"Bayat","year":"2020","journal-title":"Epilepsia."},{"key":"B4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/bjh.17753","article-title":"How we(\u2018ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future","volume":"196","author":"Risitano","year":"2022","journal-title":"Br J Haematol"},{"key":"B5","article-title":"Paroxysmal nocturnal hemoglobinuria 1","author":"Matthew","year":"","journal-title":"Pnh1"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17147","article-title":"Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease","volume":"191","author":"Luzzatto","year":"2020","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.9.5209","article-title":"Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals","volume":"96","author":"Araten","year":"1999","journal-title":"Proc Natl Acad Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.exphem.2008.09.002","article-title":"Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH","volume":"37","author":"Savage","year":"2009","journal-title":"Exp Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0140-6736(95)12360-1","article-title":"Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors","volume":"1996","author":"Soci\u00e9","year":"9027","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90201-L","article-title":"Paroxysmal nocturnal hemoglobinuria as a marker for clonal myelopathy","volume":"93","author":"Graham","year":"1992","journal-title":"Am J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01723-w","article-title":"Molecular landscape of immune pressure and escape in aplastic anemia","volume":"37","author":"Pagliuca","year":"2023","journal-title":"Leukemia."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000245","article-title":"When does a PNH clone have clinical significance","volume":"2021","author":"Babushok","year":"2021","journal-title":"Hematology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14862","article-title":"The evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy","volume":"182","author":"Bat","year":"2018","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/114.3.459","article-title":"Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin","volume":"114","author":"Brodsky","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01113-0","article-title":"Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria","volume":"35","author":"Gurnari","year":"2021","journal-title":"Leukemia."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200302000-00017","article-title":"Paroxysmal nocturnal hemoglobinuria arising from fanconi anemia","volume":"25","author":"Wainwright","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S103473","article-title":"Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasm","volume":"7","author":"Fraiman","year":"2016","journal-title":"J Blood Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12959-021-00269-8","article-title":"JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature","volume":"19","author":"Chatzidavid","year":"2021","journal-title":"Thromb J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1472","article-title":"PIG-A mutations in normal hematopoiesis","volume":"105","author":"Hu","year":"2005","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01190-9","article-title":"Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia","volume":"35","author":"Fattizzo","year":"2021","journal-title":"Leukemia."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101948","article-title":"Paroxysmal nocturnal hemoglobinuria clones in children with acquired aplastic anemia: A multicentre study","volume":"9","author":"Timeus","year":"2014","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1378432","article-title":"The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults","volume":"15","author":"Piekarska","year":"2024","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13783","article-title":"Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies","volume":"109","author":"Kulasekararaj","year":"2022","journal-title":"Eur J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14011","article-title":"Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I\/II COMPOSER trial","volume":"111","author":"R\u00f6th","year":"2023","journal-title":"Eur J Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13970","article-title":"Long-term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real-world setting","volume":"111","author":"Versmold","year":"2023","journal-title":"Eur J Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014868","article-title":"Pegcetacoplan for paroxysmal nocturnal hemoglobinuria","volume":"139","author":"Gerber","year":"2022","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"New Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003399","article-title":"The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria","volume":"135","author":"R\u00f6th","year":"2020","journal-title":"Blood."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2022006960","article-title":"Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study","volume":"6","author":"Jang","year":"2022","journal-title":"Blood Adv"},{"key":"B33","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMOA2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00315-0","article-title":"Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial","volume":"10","author":"Lee","year":"2023","journal-title":"Lancet Haematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2021011388","article-title":"Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab","volume":"138","author":"Kulasekararaj","year":"2021","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000526979","article-title":"Concomitant immunosuppressive therapy and eculizumab use in patients with paroxysmal nocturnal hemoglobinuria: an international PNH registry analysis","volume":"146","author":"Hill","year":"2023","journal-title":"Acta Haematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1973.tb01701.x","article-title":"Paroxysmal nocturnal haemoglobinuria and refractory marrow failure treated by marrow transplantation","volume":"24","author":"Storb","year":"1973","journal-title":"Br J Haematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/ejh.13176","article-title":"How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry","volume":"102","author":"Patriquin","year":"2019","journal-title":"Eur J Haematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0140-6736(79)91720-3","article-title":"Cure of aplastic an\u00e6mia in paroxysmal nocturnal h\u00e6moglobinuria by marrow transfusion from identical twin: failure of peripheral-leucocyte transfusion to correct marrow aplasia","volume":"1979","author":"Hershko","year":"8123","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-101-2-193","article-title":"Long-term survival after marrow transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia","volume":"101","author":"Szer","year":"1984","journal-title":"Ann Intern Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.2.742.bloodjournal882742","article-title":"Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: in vivo evidence that the mutant stem cells have a survival advantage","volume":"88","author":"Endo","year":"1996","journal-title":"Blood."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V66.6.1247.1247","article-title":"Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment","volume":"66","author":"Antin","year":"1985","journal-title":"Blood."},{"key":"B43","first-page":"59","article-title":"Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria","volume":"85","author":"Raiola","year":"2000","journal-title":"Haematologica."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00632-4","article-title":"Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria","volume":"29","author":"Suenaga","year":"2001","journal-title":"Exp Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00097.x","article-title":"Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria","volume":"71","author":"Lee","year":"2003","journal-title":"Eur J Haematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2015.12.005","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation for 18 patients with paroxysmal nocturnal haemoglobinuria","volume":"36","author":"Chen","year":"2015","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1179\/1607845414Y.0000000195","article-title":"Reduced-intensity stem cell allografting for PNH patients in the eculizumab era: The Mexican experience","volume":"20","author":"Schcolnik-Cabrera","year":"2015","journal-title":"Hematology."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2367","article-title":"Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: a retrospective single-center study","volume":"35","author":"Kamranzadeh Fumani","year":"2017","journal-title":"Hematol Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.02.024","article-title":"Excellent outcomes of allogeneic hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: A single-center study","volume":"25","author":"Liu","year":"2019","journal-title":"Biol Blood Marrow Transplantation."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2018.11.006","article-title":"Efficacy and safety of haploidentical hematopoietic stem cell transplantation for 17 patients with paroxysmal nocturnal hemamoglobinuria","volume":"39","author":"Xia","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2015588","article-title":"Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study","volume":"63","author":"Lu","year":"2022","journal-title":"Leuk Lymphoma."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)00264-7","article-title":"Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria","volume":"9","author":"Hegenbart","year":"2003","journal-title":"Biol Blood Marrow Transplantation."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.01.033","article-title":"Hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria in the age of eculizumab","volume":"25","author":"Cooper","year":"2019","journal-title":"Biol Blood Marrow Transplantation."},{"key":"B54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.26442\/terarkh201890757-64","article-title":"Hematopoietic stem cell transplantation with alpha\/beta T-lymphocyte depletion and short course of eculizumab in adolescents and young adults with paroxysmal nocturnal hemoglobinuria","volume":"90","author":"Shasheleva","year":"2018","journal-title":"Ter Arkh."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04214-z","article-title":"Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network","volume":"99","author":"F\u00fcreder","year":"2020","journal-title":"Ann Hematol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.062828","article-title":"Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria","volume":"97","author":"de Latour","year":"2012","journal-title":"Haematologica."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1281","article-title":"In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation","volume":"103","author":"Takahashi","year":"2004","journal-title":"Blood."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06019.x","article-title":"Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation","volume":"133","author":"Srinivasan","year":"2006","journal-title":"Br J Haematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.05.012","article-title":"Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria","volume":"20","author":"Pantin","year":"2014","journal-title":"Biol Blood Marrow Transplantation."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2019.06.005","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria compared to paroxysmal nocturnal hemoglobinuria-aplastic anemia syndrome","volume":"40","author":"Liu","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04554-4","article-title":"Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience","volume":"100","author":"Goren Sahin","year":"2021","journal-title":"Ann Hematol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2021.2021.0105","article-title":"Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia: multicenter turkish experience","volume":"38","author":"Y\u0131lmaz","year":"2021","journal-title":"Turkish J Hematology."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02982-y","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with paroxysmal nocturnal hemoglobinuria","volume":"113","author":"Nakamura","year":"2021","journal-title":"Int J Hematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.05.024","article-title":"Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: multicenter analysis by the polish adult leukemia group: allo-HSCT for paroxysmal nocturnal hemoglobinuria","volume":"26","author":"Markiewicz","year":"2020","journal-title":"Biol Blood Marrow Transplantation."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.947410","article-title":"Aplastic anemia and paroxysmal nocturnal hemoglobinuria in children and adults in two centers of Northern Greece","volume":"12","author":"Gavriilaki","year":"2022","journal-title":"Front Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27712","article-title":"Outcomes of paroxysmal nocturnal hemoglobinuria in the pediatric age group in a resource-constrained setting","volume":"67","author":"Halder","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27218","article-title":"Successful reduced-intensity conditioning hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia in two children","volume":"65","author":"Andolina","year":"2018","journal-title":"Pediatr Blood Cancer."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194416","article-title":"Fludarabine\u2013cyclophosphamide-based conditioning with antithymocyte globulin serotherapy is associated with durable engraftment and manageable infections in children with severe aplastic anemia","volume":"10","author":"Salamonowicz-Bodzioch","year":"2021","journal-title":"J Clin Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705165","article-title":"Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: A report from the EBMT-SAA Working Party","volume":"36","author":"Bacigalupo","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v91.3.756.756_756_763","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of Malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702100","article-title":"Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases","volume":"25","author":"G\u00f3mez-Almaguer","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000345","article-title":"Allogeneic hematopoietic cell transplantation in patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria clones: time for a change","volume":"4","author":"Gavriilaki","year":"2020","journal-title":"HemaSphere"},{"key":"B73","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1414799","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Yoshizato","year":"2015","journal-title":"New Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.12.507","article-title":"Current status of allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria","volume":"15","author":"Matos-Fernandez","year":"2009","journal-title":"Biol Blood Marrow Transplantation."},{"key":"B75","article-title":"Treosulfan, cyclophosphamide and antithymocyte globulin for allogeneic hematopoietic cell transplantation in acquired severe aplastic anemia","volume":"11","author":"Giebel","year":"2006","journal-title":"Ann Transplant."},{"key":"B76","unstructured":"Bierings KK\n              M\n            \n            \n              Masmas\n              T\n            \n            \n              Schmugge\n              M\n            \n            \n              Sedlacek\n              P\n            \n            \n              Sevilla BS\n              J\n            \n          \n          EWOG Consensus for treatment of SAA, Version 1.7\n          \n          2023"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004218","article-title":"Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183046","article-title":"Concurrent treatment of aplastic anemia\/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience","volume":"103","author":"Griffin","year":"2018","journal-title":"Haematologica."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.11.004","article-title":"Advances in hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria","volume":"27","author":"Du","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.01.025","article-title":"Post-allogeneic hematopoietic stem cell transplantation eculizumab as prophylaxis against hemolysis and thrombosis for patients with hematologic disorders associated with paroxysmal nocturnal hemoglobinuria clones","volume":"25","author":"Mei","year":"2019","journal-title":"Biol Blood Marrow Transplantation."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.07.032","article-title":"Eculizumab bridging before bone marrow transplant for marrow failure disorders is safe and does not limit engraftment","volume":"24","author":"DeZern","year":"2018","journal-title":"Biol Blood Marrow Transplantation."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1521484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T02:18:50Z","timestamp":1736216330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1521484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":81,"alternative-id":["10.3389\/fimmu.2024.1521484"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1521484","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1521484"}}